Merck, Daiichi Sankyo Withdraw Application for Accelerated Approval of Lung Cancer Treatment
Daiichi Sankyo Co Ltd 4568
News
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
AstraZeneca, Daiichi Breast-Cancer Drug Gets Nod in England After U.S. Pharma Deal
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
AstraZeneca, Daiichi Sankyo Get New EU Approval for Breast Cancer Drug
DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review — Update
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
Breast Cancer Treatment from Daiichi Sankyo, AstraZeneca Approved in U.S.
Shares of Japanese Drugmaker Daiichi Sankyo Tumble on Delay in Earnings
Daiichi Sankyo to Sell Over-the-Counter Drug Business for $1.55 Billion
AstraZeneca, Daiichi Sankyo Drug Gets U.S. Nod for Breast-Cancer Label Expansion
AstraZeneca and Daiichi Sankyo's Datroway Shows Meaningful Improvement for Breast Cancer Patients
AstraZeneca shares leap with FDA set to review drug to treat breast cancer
United States